Saturday 17 October 2026
Export CRDF’s income statement to Excel — free account
Cardiff Oncology, Inc.
CRDF Healthcare Biotechnology
Cardiff Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $593,000.00, down 13.2% from fiscal 2024. In the quarter to June 2026, revenue fell 14.1%, EPS grew 33.3% and free cash flow fell 41.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.90
0.07
−7.22%
Follow CRDF
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
275.54 | 316.73 | 210.91 | 175.03 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(12.72) | (31.48) | (9.01) | (7.56) | |
P/B ratio |
2.82 | 4.14 | 3.19 | 3.35 | |
Price to Tangible BV |
2.82 | 4.14 | 3.19 | 3.35 | |
EV/Sales |
157.18 | 220.79 | 125.87 | 109.85 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.86) | (3.45) | (1.77) | (1.37) | |
EV/FCF |
(1.86) | (3.45) | (1.76) | (1.36) | |
Quick Ratio |
4.14 | 3.57 | 3.20 | 3.21 | |
Current Ratio |
4.20 | 3.67 | 3.27 | 3.30 | |
Net Debt/EBITDA |
4.99 | 7.38 | 3.58 | 3.60 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
0.96 | 0.83 | 0.99 | 1.27 | |
Capex/Depreciation |
0.11 | 0.00 | 0.00 | (1.91) | |
Research and Development Expense of Revenue |
6,830.83% | 2,088.48% | 16,500.00% | 5,687.50% | |
Selling, General and Administrative Expense of Revenue |
3,247.50% | 1,232.51% | 14,941.46% | 3,657.69% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1,153.33% | 518.93% | 4,048.78% | 884.62% | |
Graham Net Nets |
0.34 | 0.23 | 0.30 | 0.28 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(38.35%) | (24.56%) | (41.36%) | (46.15%) | |
Free Cash Flow Yield |
(30.68%) | (20.21%) | (33.83%) | (46.05%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.16) | (0.09) | (0.18) | (0.17) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.16) | (0.09) | (0.18) | (0.17) | |
Cash per Share |
0.91 | 0.87 | 0.67 | 0.50 | |
Shareholders Equity per Share |
0.73 | 0.68 | 0.51 | 0.39 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.73 | 0.68 | 0.51 | 0.39 | |
Free Cash Flow |
(10.85) | (5.97) | (12.29) | (11.81) | |
Working Capital |
47.10 | 43.73 | 32.88 | 24.80 | |
Capital Expenditures |
(0.02) | 0.00 | — | (0.04) | |
Net Current Asset Value |
46.81 | 43.63 | 32.88 | 24.80 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.15 | 0.00 | 0.00 | 0.42 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.44 | 0.48 | 0.30 | 0.36 | |
Average Payables |
3.54 | 6.45 | 4.55 | 5.00 | |
Average Assets |
63.34 | 79.54 | 66.99 | 56.53 | |
Average Common Equity |
49.09 | 64.17 | 52.79 | 42.57 |
Columns are period end dates